| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 1
Mitragyna inermis (Willd.) O. Kuntze ethnopharmacology and metabolic disorders: An update review and in silico study
1 Nazi BONI University, Laboratory of Research and Teaching in Animal Health and Biotechnologies, Bobo-Dioulasso, Burkina Faso2 Karachi University, H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, Karachi, Pakistan
3 Nazi BONI University, Department of Biochemistry-Microbiology, Life and Earth Sciences Training and Research Unit, Bobo-Dioulasso, Burkina Faso
4 Karachi University, International Center for Chemical and Biological Sciences, Dr. Panjwani Center for Molecular Medicine and Drug Research, Karachi, Pakistan
DOI : 10.23893/1307-2080.APS6302 Viewed : 3339 - Downloaded : 1728 Mitragyna inermis is a wild plant whose parts are traditionally used. However, there is no particular report on the compounds bioactivity evidence against metabolic disorders. We carried out a literature review of this plant uses and compounds mostly isolated in diabetic and hypertensive states. Following the review, we carried out an in silico study on major targets for research into antidiabetic and antihypertensive candidates. From this study, it emerged that the plant is used in the treatment of diabetes and hypertension. The main compounds isolated from this plant were terpenoids and alkaloids. The in silico study revealed that these compounds could inhibit ?-amylase, ?-glucosidase and sodium glucose co-transporter 2 in diabetic status, as well as angiotensin converting enzyme in hypertensive status. Most of these compounds could be absorbed and metabolized on the basis of ADME (Adsorption, Distribution, Metabolism and Excretion) pharmacokinetic prediction. Further studies are needed to optimize its activities and conduct in vitro trials. Keywords : Mitragyna inermis, metabolic disorders, in silico study, diabetes, hypertension